文献速递免疫规划慢病防控与筛查

丹麦2017至2024年女孩期接种HPV疫苗女性第一、二、三次宫颈细胞样本中人乳头瘤病毒流行率:Trial23队列研究数据

Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study.
PubMed 文献 · Euro Surveill · 2025-01-01

研究基于丹麦Trial23队列,2017年2月至2024年2月检测女孩期接种四价HPV疫苗女性宫颈细胞样本的HPV16/18及非疫苗高危型HPV。接种女性HPV16/18流行率在三份连续样本中分别为0.4%、0.3%、0.2%,非疫苗高危型为32%、28%、31%;接种者HPV16/18持续率为40%,非疫苗高危型为53%。调整分析显示接种者HPV16/18发病率显著更低(aRR<0.10),非疫苗高危型发病率更高(aRR=1.66)。

要点

  • 女孩期接种四价HPV疫苗女性HPV16/18流行率在三份连续样本中为0.4%、0.3%和0.2%。
  • 接种女性非疫苗高危型HPV流行率为32%、28%和31%,持续率为53%。
  • 调整分析中接种者HPV16/18发病率aRR<0.10,非疫苗高危型aRR=1.66(95%CI:1.12-2.45)。

核心结论

  • 研究提供真实世界证据,显示女孩期接种四价HPV疫苗女性对HPV16/18感染具有稳定保护。
  • 在九价疫苗接种女性达到筛查年龄前,较低强度筛查似乎合理,届时应重新考虑筛查策略。

研究设计与样本

  • 研究为Trial23队列研究,属于国家筛查规划的一部分。
  • 2017年2月至2024年2月,对细胞学分析后剩余样本检测HPV16/18及非疫苗高危型HPV。
  • 共8,659名女性提供至少一份样本,5,835名至少两份,2,461名至少三份;7,800名接种女性纳入分析。

主要发现

  • 接种女性三份连续样本中HPV16/18流行率分别为0.4%(95%CI:0.2-0.5)、0.3%(95%CI:0.1-0.4)和0.2%(95%CI:0.0-0.4)。
  • 接种女性非疫苗高危型HPV流行率分别为32%(95%CI:31-33)、28%(95%CI:27-29)和31%(95%CI:29-33)。
  • 接种女性HPV16/18持续率为40%,非疫苗高危型HPV持续率为53%。
  • 调整分析比较接种与未接种女性,HPV16/18发病率显著更低(aRR<0.10),非疫苗高危型HPV发病率更高(aRR=1.66;95%CI:1.12-2.45)。
  • 持续率方面未观察到显著差异。

临床怎么用

  • 作者认为,在九价疫苗接种女性达到筛查年龄前,较低强度筛查似乎合理,届时应重新考虑筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDDanish women vaccinated with the 4-valent human papillomavirus (HPV) vaccine (HPV types: 6/11/16/18) at age 14 in 2008 reached screening age in 2017, allowing assessment of long-term effects on prevalence, persistence and incidence of HPV infections.AIMTo examine the HPV status of cervical samples over time among women vaccinated as girls.METHODSBetween February 2017 and February 2024, residual material from cytology-analysed samples collected through the 'Trial23' study, part of the national screening programme, was tested for HPV16/18 and non-vaccine high-risk (HR) HPV types. Prevalence in first, second and third samples, and persistence and incidence between samples were calculated.RESULTSOver 7 years, 8,659 women provided at least one sample, 5,835 at least two and 2,461 at least three. In 7,800 vaccinated women, HPV16/18 prevalence was 0.4% (95% confidence interval (CI): 0.2-0.5), 0.3% (95% CI: 0.1-0.4) and 0.2% (95% CI: 0.0-0.4) in three consecutive samples. Prevalence of non-vaccine HR HPV was 32% (95% CI: 31-33), 28% (95% CI: 27-29) and 31% (95% CI: 29-33). Persistence of HPV16/18 and non-vaccine HPV among vaccinated women was 40% and 53%. In adjusted analyses comparing vaccinated vs unvaccinated women, incidence was significantly lower for HPV16/18 (adjusted relative risk (aRR) < 0.10) while incidence of non-vaccine HR HPV types was higher (aRR: 1.66; 95% CI: 1.12-2.45). No significant difference was observed for persistence.CONCLUSIONOur study provides real-world evidence of stable protection against HPV16/18 infections in women vaccinated as girls. Less intensive screening seems reasonable until women vaccinated with the 9-valent vaccine reach screening age, when screening should be reconsidered.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Nonboe MH, Napolitano GM, Schroll JB, et al. Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study. Euro Surveill. 2025. PMID: 40642768. doi:10.2807/1560-7917.ES.2025.30.27.2400820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。